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AbstrAct
Objectives Bacterial meningitis remains an important 
cause of morbidity and mortality worldwide. Its 
epidemiological characteristics, however, are changing due 
to new vaccines and secular trends. Conjugate vaccines 
against Haemophilus influenzae type b and Streptococcus 
pneumoniae (10-valent) were introduced in 1986 and 
2010 in Finland. We assessed the disease burden and 
long-term trends of five common causes of bacterial 
meningitis in a population-based observational study.
Methods A case was defined as isolation of S. 
pneumoniae, Neisseria meningitidis, Streptococcus 
agalactiae, Listeria monocytogenes or H. influenzae from 
cerebrospinal fluid and reported to national, population-
based laboratory surveillance system during 1995–2014. 
We evaluated changes in incidence rates (Poisson or 
negative binomial regression), case fatality proportions (χ2) 
and age distribution of cases (Wilcoxon rank-sum).
Results During 1995–2014, S. pneumoniae and N. 
meningitidis accounted for 78% of the total 1361 reported 
bacterial meningitis cases. H. influenzae accounted for 
4% of cases (92% of isolates were non-type b). During 
the study period, the overall rate of bacterial meningitis 
per 1 00 000 person-years decreased from 1.88 cases 
in 1995 to 0.70 cases in 2014 (4% annual decline (95% 
CI 3% to 5%). This was primarily due to a 9% annual 
reduction in rates of N. meningitidis (95% CI 7% to 10%) 
and 2% decrease in S. pneumoniae (95% CI 1% to 4%). 
The median age of cases increased from 31 years in 
1995–2004 to 43 years in 2005–2014 (p=0.0004). Overall 
case fatality proportion (10%) did not change from 2004 to 
2009 to 2010–2014.
Conclusions Substantial decreases in bacterial meningitis 
were associated with infant conjugate vaccination 
against pneumococcal meningitis and secular trend in 
meningococcal meningitis in the absence of vaccination 
programme. Ongoing epidemiological surveillance is 
needed to identify trends, evaluate serotype distribution, 
assess vaccine impact and develop future vaccination 
strategies.
IntroductIon
Despite the availability of vaccines, anti-
biotics and advances in intensive care, 
bacterial meningitis remains an important 
cause of morbidity and mortality worldwide. 
Persistent neurological sequelae including 
hearing loss, neuropsychological impair-
ment or seizures are reported in 10%–30% 
of survivors.1 The case fatality proportion 
(CFP) ranges from 5% to 30% for different 
bacteria.2 3
Globally, Streptococcus pneumoniae, Neis-
seria meningitidis and Haemophilus influenzae 
are the most important causes of bacterial 
meningitis, particularly in young children.4 5 
Among neonates, the most common cause 
of bacterial meningitis is S. agalactiae,2 6 
while Listeria monocytogenes is important in 
newborns and elderly persons with comor-
bidities.7 However, the leading organisms 
causing bacterial meningitis vary by age of 
the patient, time and geographical location.5 
As the choice of empirical antimicrobial 
treatment for bacterial meningitis should 
be based on local epidemiology, patient’s 
age, presence of risk factors and regional 
resistance patterns,8–10 population-based 
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Strengths and limitations of this study
 ► This study describes the epidemiological 
characteristics of  >1300 cases of bacterial 
meningitis reported to national surveillance during 
20 years in Finland.
 ► The study provides clinically important information 
on the changing distribution of pathogens and age 
of cases.
 ► The study documents the sustained population 
impact of infant conjugate vaccination against 
Haemophilus influenzae type b; and introduction 
of 10-valent pneumococcal conjugate vaccination 
on reducing the burden of bacterial meningitis, as 
well as decline in meningococcal meningitis due 
to secular trend. As the data were from laboratory-
based surveillance system, clinical information such 
as severity or treatment was not available.
 ► Incidence rate of bacterial meningitis may be 
underestimated since cases diagnosed by PCR or 
antigen detection and culture-negative meningitis 
cases diagnosed based on clinical symptoms and 
findings were not included in the  dataset.
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surveillance data are important to help in formulating 
clinical guidelines.
The introduction of effective protein conjugate vaccines 
against H. influenzae type b (Hib), S. pneumoniae and N. 
meningitidis has changed the epidemiology of bacterial 
meningitis in many countries.11 12 In Finland, universal 
vaccination against Hib since 1986 resulted in rapid elim-
ination of the disease13 and introduction of the 10-valent 
pneumococcal conjugate vaccine (PCV10) in September 
2010 has resulted in substantial reduction in vaccine-type 
invasive disease.14 15 Meningococcal conjugate vaccines 
(MCVs) have not been introduced into Finnish National 
Vaccination Programme (NVP). However, meningo-
coccal polysaccharide vaccine has been offered to military 
conscripts since 1982.
To provide information for developing future preven-
tion strategies and to help in formulating clinical 
guidelines, we conducted a population-based observa-
tional study to determine the contribution of specific 
pathogens to the total bacterial meningitis disease 
burden and to assess long-term trends in the incidence of 
common aetiologies in Finland during 1995–2014.
MaterIals and Methods
data sources
Since 1995, all clinical microbiology laboratories in 
Finland have had legal obligation to report microbial 
isolations from blood and/or cerebrospinal fluid (CSF) 
to the National Infectious Diseases Register (NIDR)—a 
population-based, electronic laboratory surveillance 
system maintained by the National Institute for Health 
and Welfare (THL). Routinely collected information 
include the microbe, specimen date, date of birth, sex, 
place of residence and unique Personal Identity Code 
(PIC). For blood or CSF findings concerning S. pneumo-
niae, S. agalactiae, N. meningitidis, L. monocytogenes or H. 
influenzae, multiple notifications with the same PIC and 
microbe are merged into one case if they occurred within 
3 months of the first notification. Since 2004, information 
on vital status after episode is routinely obtained from the 
Population Information System. All clinical microbiology 
laboratories also submit isolates from reported cases to 
THL reference laboratories for species verification and 
characterisation of the isolates including serotyping or 
serogrouping. Since 2004, serotyping results are linked 
to NIDR notifications by using the PIC. Antimicrobial 
susceptibility data were not available.
case definitions
We defined a case of bacterial meningitis as isolation of S. 
pneumoniae, S. agalactiae, N. meningitidis, L. monocytogenes 
or H. influenzae from CSF and notified to NIDR from 1995 
through 2014.
For cases reported during 2004–2014, we calculated the 
pathogen-specific 30-day CFP as number of cases resulting 
in death within 30 days from the first positive CSF culture, 
divided by all cases.
We calculated the proportions of S. pneumoniae, N. 
meningitidis and H. influenzae cases due to vaccine-prevent-
able serotypes/serogroups during 2004–2014. Serotypes 
covered in PCV10 are the following: 1, 4, 5, 6B, 7F, 9V, 
14, 18C, 19F and 23F; the 13-valent PCV13 adds serotypes 
3, 6A and 19A. Vaccine-preventable meningococcal sero-
groups include those in the quadrivalent MCV (MCV-4, 
A, C, W and Y) and serogroup B isolates targeted by novel 
protein-based vaccines (MenB). For H. influenzae, type b 
was considered vaccine preventable.
statistical analysis
By using data from the Population Information System 
as denominators, we calculated pathogen-specific and 
age-specific annual incidence rates. Poisson regression 
was used to test for log-linear trend in rates of bacte-
rial meningitis during 1995–2014. Incidence rate ratios 
(IRRs), their 95% CI and p values for yearly changes were 
calculated using time (year) as a continuous explanatory 
variable in the Poisson model. When appropriate, we used 
negative binomial regression to correct for overdisper-
sion of data. To compare age distribution of cases across 
years, we used Wilcoxon rank-sum test. To assess changes 
in CFP, we used χ2 analyses; p value <0.05 was considered 
statistically significant. All analyses were done with STATA 
version 13 and Microsoft Excel 2013.
ethical considerations
Data used in the analysis were collected as a part of 
national routine surveillance which falls under the 
existing mandate of THL. No formal Institutional Review 
Board review was required for this study. Personal identi-
fiers were removed after linkage with vital status data.
results
overall incidence rates of bacterial meningitis
From 1995 to 2014, 1361 cases of bacterial meningitis 
caused by S. pneumoniae, N. meningitidis, S. agalactiae, L. 
monocytogenes or H. influenzae were reported (mean inci-
dence rate, 1.29 cases/100 000 person-years, table 1). S. 
pneumoniae and N. meningitidis were the most common 
aetiologies accounting for 78% (1061/1361) of cases. The 
median age of cases increased from 31 years in 1995–2004 
to 43 years in 2005–2014 (p=0.0004). Rates were higher 
in men than women (1.52 vs 1.07 cases/100 000 person-
years; IRR 1.4, 95% CI 1.3 to 1.6)).
The mean annual rates of all bacterial meningitis 
ranged from 1.97 in 1996 to 0.70 cases/100 000 person-
years in 2014, with an annual decrease of 4% (95% CI 
−3% to −5%, table 1). During 2004–2014, 65 patients died 
within 30 days from culture (CFP, 10% (65/633)). There 
was no change in 30-day CFP from 2004–2009 (11% 
(43/402) to 2010–2014 (10% (22/231), p=0.22.
characteristic of bacterial meningitis by age group
Children <2 years of age accounted for 20% of cases 
(268/1361) and had the highest incidence rate (11.38 
cases/100 000 person-years, table 1). The most common 
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pathogens in this age group were S. agalactiae (4.50 
cases/100 000 person-years) and S. pneumoniae (3.52 
cases/100 000 person-years, figure 1). From 1995 to 2014, 
the rate of bacterial meningitis in this age group decreased 
by 2% annually (95% CI −4% to −1%, table 1). The average 
30-day CFP in 2004–2014 was 2% (3/140). In children 2–4 
years of age, 70 cases (5%) of bacterial meningitis were 
reported during 1995 to 2014 (1.94 cases/100 000 person-
years). The most common pathogens in this age group 
were N. meningitidis (1.33 cases/100 000 person-years) 
and S. pneumoniae (0.50 cases/100 000 person-years, table 
1). During the study period, the rate of all meningitis 
did not change significantly (table 1). The 30-day CFP in 
2004–2014 was 14% (4/128); all four deaths were due to 
N. meningitidis.
Children 5–17 years of age accounted for 130 cases 
(9%) of bacterial meningitis and had the lowest rate 
(0.80 cases/100 000 person-years, table 1). N. meningitidis 
and S. pneumoniae were the main causes (0.52 and 0.20 
cases/100 000 person-years, respectively, figure 1). From 
1995 to 2014, the rate of bacterial meningitis decreased 
by 8% annually (95% CI −12% to −4%, table 1). The 
30-day CFP was 7% (3/45); all three fatal cases were due 
to N. meningitidis.
Adults 18–49 years of age accounted for 408 cases 
(30%) of bacterial meningitis (0.91 cases/100 000 person-
years, table 1). N. meningitidis and S. pneumoniae caused 
most of the cases (figure 1), with incidence rates 0.43 
and 0.40 cases/100 000 person-years, respectively. During 
1995–2014, the overall rate decreased by 7% annually 
(95% CI −8% to −5%, table 1). The 30-day CFP was 8% 
(13/152), with nine deaths due to S. pneumoniae infection.
Among persons 50–64 years of age, there were 274 cases 
(20%) of bacterial meningitis (1.30 cases/100 000 person-
years, table 1), of which 186 cases (68%) were caused by 
S. pneumoniae (0.88 cases/100 000 person-years, figure 1). 
During the study period, the overall rate decreased by 4% 
annually (95% CI −6% to −2%, table 1). The 30-day CFP 
was 13% (18/143), with most fatal cases attributable to S. 
pneumoniae (16 deaths).
In adults ≥65 years of age, there were 211 cases (15%) 
of bacterial meningitis (1.23 cases/100 000 person-
years, table 1). S. pneumoniae caused 53% (113/211) of 
the cases (0.66 cases/100 000 person-years), followed by 
L. monocytogenes. There was no significant change in the 
overall rate during 1995–2014 (table 1). This age group 
had the highest 30-day CFP (19%, 24/125). Half of the 
fatal cases were due to S. pneumoniae (12 deaths); L. mono-
cytogenes caused 10 deaths.
causes of bacterial meningitis
Streptococcus pneumoniae
From 1995 to 2014, 611 cases of pneumococcal menin-
gitis were reported. Median age was 48 years; 57% of 
cases were male (male to female IRR, 1.4 95% CI 1.2 
to 1.6, table 2). The overall annual rate per 1 00 000 
person-years decreased from 0.70 in 1995 to 0.26 in 
2014 (figure 2), a 2% annual decrease (95% CI −4% to 
−1%, table 1).
 The incidence of pneumococcal meningitis decreased 
annually by 4% (95% CI −7% to 0%), 7% (95% CI −13% 
to −1%) and 4% (95% CI −6% to −1%) in age groups 
<2 years, 5–17 years and 18–49 years, respectively. 
During 2004–2014, S. pneumoniae accounted for 58% 
(38/65) of fatal cases (30-day CFP 12%, 38/308).
Of the 308 pneumococcal meningitis cases reported 
during 2004–2014, information on serotype was available 
for 296 (96%). The proportion of cases caused by PCV10 
serotypes decreased from 61% (35/57) in 2004–2005 to 
15% (9/36) in 2013–2014. PCV13 serotypes accounted 
for 70% (40/57) cases in 2004–2005 and 44% (16/36) 
in 2013–2014. In children less than 2 years, proportion 
of meningitis cases caused by PCV10 serotypes decreased 
from 75% (9/12) in 2004–2005 to 20% (1/5) in 2013–
2014. In 2014, no meningitis cases were caused by PCV10 
serotypes.
Neisseria meningitidis
During the study period, meningococcal meningitis 
accounted for 450 cases (0.43 cases/100 000 person-years) 
(table 1). Median age was 18 years and 60% of cases were 
male (male to female IRR 1.5, 95% CI 1.3 to 1.9, table 
2). The overall annual incidence per 1 00 000 person-
years decreased from 0.88 in 1995 to 0.07 in 2014; the 
annual decrease was −9% (95% CI −7% to −10%, table 1). 
The decline occurred in all age-groups except in <2 years 
Figure 1 Proportions of bacterial meningitis cases caused by five pathogens according to age group, Finland, 1995–2014.
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and ≥65 years of age. The incidence decreased annually by 
6% (95% CI −1% to −10%), 8% (95% CI −3% to −14%), 
10% (95% CI −8% to −13%) and 12% (95% CI −8% 
to −13%) in age groups 2–4 years, 5–17 years, 18–49 years 
and 50–64 years, respectively. The overall 30-day CFP was 
9% (14/163) and ranged from 3% (1/29) among chil-
dren aged 0–1 years to 21% (4/19) among children aged 
2–4 years.
During 2004–2014, information on N. meningitidis 
serogroups was available for 99% of cases (161/163). 
Serogroup B accounted for 85% (137/161) of isolates, 
C 11% (17/161) and Y 4% (7/161). In children <2 years, 
serogroup B caused 96% (26/27) of cases. MCV-4 and 
MenB vaccine serogroups caused 15% (24/161) and 85% 
(137/161) of all cases, respectively.
Haemophilus influenzae
From 1995 to 2014, 58 cases of H. influenzae were reported 
(0.06 cases/100 000 person-years, table 1). Median age 
was 29 years and male to female IRR was 1.0 (95% CI 0.6 
to 1.7, table 2). The incidence rate ranged from 0.0 cases 
per 1 00 000 person-years in 2010 to 0.25 cases in 2007 
(figure 2). Rates in all age groups were stable. From 2004 
to 2014, there were no deaths due to H. influenzae.
In 2004–2014, non-encapsulated H. influenzae 
accounted for 69% (18/26) , serotype f 23% (6/26) and 
type b 8% (2/26) of isolates.
Streptococcus agalactiae
Infection with S. agalactiae accounted for 141 cases of 
meningitis (0.13 cases/100 000 person-years), including 
24 early-onset cases and 78 late-onset cases (table 1). 
The median age of cases was 30 days; male to female IRR 
was 1.03 (95% CI 0.7 to 1.4) (table 2). During the study 
Table 2 Characteristics of bacterial meningitis cases, Finland, 1995–2014
Characteristics S. pneumoniae N. meningitidis S. agalactiae
L.  
monocytogenes H.  influenzae Total
Gender,
no of cases (% 
of total)
  Male 347 (57) 268 (60) 70 (50) 71 (70) 28 (48) 784 (58)
  Female 264 (43) 182 (40) 71 (50) 30 (30) 30 (52) 577 (42)
Age (years)
  Median 48 18 0 68 29 36
  IQR 28–62 4–35 0 56–74 6–54 5–58
Case fatality*
  No of deaths 
(no of cases) 38 (308) 14 (163) 2 (86) 11 (50) 0 (26) 65 (633)
  Case fatality 
proportion (%) 12.3 8.6 2.3 22 0 10.3
*Data are for cases reported during 2004–2014. 
Figure 2 Incidence rate (per 100 000 person-years) of bacterial meningitis by year and pathogen, Finland, 1995–2014.
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period, annual rates ranged from 0.06 cases/100 000 
person-years in 1995 to 0.17 cases in 2014 (figure 2), but 
overall rates of S. agalactiae did not change significantly 
(p=0.97, table 1). During 2004–2014, the 30-day CFP was 
2% (2/86).
Listeria monocytogenes
During the study period, L. monocytogenes caused 101 cases 
of meningitis (0.13 cases/100 000 person-years), mostly 
among elderly persons (median age, 68 years). Of cases, 
70% were men (male to female IRR 2.5, 95% CI 1.6 to 
3.9, table 2). Overall incidence rates of Listeria meningitis 
did not vary significantly during the study period, ranging 
from 0.04 to 0.21/100 000 person-years (table 1). The 
overall 30-day CFP was 22% (11/50) and 28% (10/36) in 
persons ≥65 years of age.
dIscussIon
During 1995–2014, the most common causes of bacterial 
meningitis in Finland were S. pneumoniae and N. meningit-
idis. However, contribution of specific pathogens to the 
disease burden varied substantially by age. As in other 
developed countries, S. agalactiae was the most common 
cause of bacterial meningitis in children <1 years of age.6 
The mean age of cases increased significantly during 
the study period mainly because of the decrease in inci-
dence in children associated with PCV10 programme and 
declining secular trend in meningococcal meningitis.
During the study period, significant declines were seen 
in overall incidence of bacterial meningitis—primarily 
due to decreases in rates of N. meningitis and S. pneu-
moniae. Of interest, the decrease in incidence of N. 
meningitidis was greater than for pneumococcal menin-
gitis, although there is no routine vaccination programme 
for meningococcal disease in Finland. Changes in rates of 
meningococcal disease have also been observed in other 
countries in Europe and worldwide.16 17 The reasons 
for these declines in incidence are not clear but may be 
related to population immunity to circulating strains, 
changes in colonising organisms in the nasopharynx 
or increasing use of influenza vaccine. Also, changes 
in behavioural risk factors such as lower prevalence 
of smoking or crowding might contribute.18 19 In some 
countries, decreases were related to meningococcal vacci-
nation. After the introduction of conjugate serogroup C 
meningococcal vaccine, vaccine serogroup disease nearly 
disappeared in England20 and the Netherlands.21 Direct 
and indirect (herd protection) vaccine effects were also 
reported from other European countries including 
Spain, Ireland and Belgium.22 23 Immunisation of high 
risk groups with recently licensed protein-based vaccines 
targeted against meningococcal serogroup B might also 
be considered in Finland. However, updated cost-effective 
analysis is needed for decision-making about introduc-
tion of meningococcal vaccination programs.
Before the introduction of PCV10, considerable vari-
ation in pneumococcal meningitis incidence rates was 
seen. As there were no major changes in surveillance 
or diagnostic practices in Finland, these changes may 
be related to emergence of new serotypes, selective 
pressure from antibiotic use or natural fluctuation in 
serotypes.24–26 The decline in pneumococcal meningitis 
incidence in children <2 years of age was associated with 
introduction of PCV10 in the NVP in 201015; PCV10 sero-
types in this age group were significantly reduced and by 
2014 no vaccine serotype meningitis cases were reported. 
In vaccine-eligible children, the overall rate of pneumo-
coccal meningitis was reduced by 46% as a result of a 
69% reduction in PCV10-type meningitis.15 Many studies 
in USA and Europe have also documented significant 
declines in the incidence of pneumococcal meningitis in 
both vaccinated and unvaccinated groups after introduc-
tion of PCV programmes.11 12 27–29 In Finland, it might be 
possible to achieve further reductions with higher valency 
conjugate vaccine formulations.
The incidence rate of L. monocytogenes, N. meningitidis 
and S. pneumoniae was higher in men than women. L. 
monocytogenes meningitis cases were 2.5 times more likely 
to be men. Higher rates of listeriosis in males have also 
been observed in other studies.7 However, the reasons 
are unknown, but may be related to higher prevalence of 
underlying conditions, alcoholism among men and liver 
diseases (including alcoholic cirrhosis).30 In pneumo-
coccal and meningococcal meningitis, possible reasons 
may be higher prevalence of underlying medical condi-
tions,smoking and alcoholism.31 As listeriosis is primarily 
transmitted through contaminated food, important 
prevention efforts include health education about dietary 
guidelines for high risk groups, such as pregnant women 
and the elderly.32
The overall 30-day CFP for meningitis did not change 
significantly during 1995–2014. However, the unchanged 
CFP may be related to the altered age distribution of 
cases. Older age is associated with higher risk of poor 
outcome.33 In addition, pathogen distribution has 
changed and the case fatality for meningococcal menin-
gitis is lower compared with pneumococcal meningitis. 
The small number of fatal cases in our study did not allow 
assessing changes in CFP by age group and pathogen. The 
30-day CFP was highest for L. monocytogenes (22%), which 
is comparable with results from the Netherlands and 
Spain.7 34 Most of the fatal cases of bacterial meningitis in 
persons ≥50 years were attributable to S. pneumoniae. Cases 
who had pneumococcal meningitis were older than those 
who were infected with other encapsulated bacteria and 
likely had higher prevalence of comorbidities increasing 
the risk of pneumococcal infection and poor outcome.35 
Because of lack of clinical data, we could not assess the 
potential impact of treatment changes, such as dexa-
methasone use, on case fatality. The relatively high CFP 
emphasises the importance of immediate initiation of 
treatment and supportive care after diagnosis to improve 
outcome of bacterial meningitis.
As expected, H. influenzae was the least common cause of 
bacterial meningitis. However, the stable number of cases 
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over 20 years suggest existence of small group of individ-
uals with risk factors for H. influenzae (such as chronic 
respiratory disease and impaired immunity).36 Conju-
gate vaccination has nearly eliminated Hib meningitis in 
many high-income countries.37 38 However, changes in the 
epidemiology of invasive H. influenzae have been observed 
and currently most cases occur in adults39 and non-encap-
sulated, non-typable H. influenzae have dominated since 
2004.
Because the data on laboratory confirmed cases are 
transmitted electronically directly from the clinical micro-
biology laboratories’ database to the national surveillance 
database, a strength of our study is comprehensive case 
ascertainment. In addition, almost all isolates of N. 
meningitidis, H. influenzae and S. pneumoniae (98%) were 
available for serotyping/grouping at THL reference 
laboratory. However, our study has several limitations. As 
the data were from laboratory-based surveillance system, 
information on clinical presentation or treatment was not 
available. Therefore, culture-negative meningitis cases 
diagnosed on the basis of clinical symptoms and findings 
were not included in the analysis dataset. In addition, 
cases diagnosed by PCR or antigen detection were not 
included. As CSF cultures are negative in 11%–30% of 
patients with bacterial meningitis,40 the total number of 
meningitis cases is underestimated. Another limitation is 
that NIDR database does not include information on the 
cause of death. However, most of deaths associated with 
bacterial meningitis occur early (within 14 days of admis-
sion), suggesting that they were related to the infection.41
In conclusion, this study describes the epidemiolog-
ical characteristics of >1300 cases of bacterial meningitis 
reported to national surveillance over 20 years. It docu-
ments the sustained population impact of infant conjugate 
vaccination against Hib and introduction of PCV  on 
reducing burden of bacterial meningitis as well as decline 
in meningococcal meningitis due to secular trend. 
However, disease burden had shifted to older people and 
no changes in the overall proportion of fatal cases were 
seen. Data on changes in causative organisms and age 
distribution for meningitis cases are important for eval-
uating clinical guidelines for empirical antibiotic therapy 
in bacterial meningitis. Continued epidemiological 
surveillance is necessary to monitor changing trends and 
serotype distribution, assessing the impact of vaccination 
programs and developing future vaccination strategies.
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